section name header

Information

AHFS Class:

28:08.04.04 Reversible COX-1/COX-2 Inhibitors

Products

Ibuprofen lysinate is available as a preservative-free solution containing in each mL the L-lysine salt of (±) ibuprofen 17.1 mg (equivalent to ibuprofen 10 mg) with sodium hydroxide or hydrochloric acid to adjust pH during manufacturing in water for injection.3540 The injection is packaged in single-use 2-mL vials.3540 CAUTION: Care should be taken to ensure that the correct drug product, dose, and administration procedures are used and that no confusion with other products (e.g., ibuprofen [Caldolor]) occurs.

pH

The pH of the solution is adjusted to 7.3540

Trade Name(s)

NeoProfen

Administration

Ibuprofen lysinate is administered intravenously using the intravenous port that is nearest the insertion site following dilution of the drug to a suitable volume with dextrose or saline infusion solution.3540 The drug should be prepared and administered within 30 minutes of preparation by intravenous infusion over 15 minutes taking care to avoid extravasation.3540

The manufacturer states that administration of the drug using an umbilical arterial line has not been evaluated.3540

Stability

Intact vials of ibuprofen lysinate should be stored at controlled room temperature protected from light.3540 The manufacturer recommends retaining the vials in their carton until use.3540

After dilution to an appropriate volume with dextrose or saline intravenous infusion solution, ibuprofen lysinate should be administered within 30 minutes over a period of 15 minutes.3540 Any remaining solution in the single-use vials should be discarded because no antimicrobial preservative is present.3540 The manufacturer recommends not administering ibuprofen lysinate into a line running a total parenteral nutrition (TPN) admixture; the TPN should be interrupted if necessary for 15 minutes both before and after administering ibuprofen lysinate maintaining line patency using dextrose or saline infusion solution.3540

Compatibility

Solution Compatibility

Y-Site Injection Compatibility (1:1 Mixture)

Other Info

References

For a list of references cited in the text of this monograph, search the monograph titled References.

Copyrights

ASHP® Injectable Drug InformationTM. Selected Revisions December 5, 2024. © Copyright, 2024. American Society of Health-System Pharmacists®, 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.